Altimmune Stock (NASDAQ:ALT), Trade Ideas

Altimmune

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABTS

AKAN

ALLG

AVTX

BDRX

BRZE

CERO

CZOO

DTST

DXYZ

GCTS

GMDA

HKIT

Kintara Therapeutics, Inc. - Common Stock

KTRA

MARA

MLKN

MRNO

MSTR

MTTR

MVLA

NCNA

NKLA

NTRB

OTRK

PMEC

PRST

RDDT

SEZL

SMMT

SOBR

STRO

TNXP

UGRO

XXII

Shares of  Kodiak Sciences Inc.  (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss.

Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share.

Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

ARHS

DOOO

EXAS

OPEN

RIOT

U.S. stocks were slightly higher, with the S&amp;P 500 gaining around 0.1% on Thursday.

Shares of REX American Resources Corporation (NYSE: REX) rose sharply during Thursday’s session following upbeat quarterly earnings.

REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday

Biotech

Earnings

Guidance

Health Care

General

BHVN

Latest findings on Altimmune&#39;s pemvidutide on body composition: lean mass preservation, significant weight loss from adipose tissue, and results in obesity and Metabolic dysfunction-associated steatohepatitis trials.

Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?

Altimmune Inc

Alitas

Morella Corp Ltd

ALPINE AUTO BROKERS INC by Alpine Auto Brokers Inc

Alpine Auto Brokers Inc

ALTITUDE INTL INC by Altitude International Holdings, Inc.

Altitude International Holdings Inc

Altitude Acquisition Corp. II

Alta Equipment Group Inc. Class A Common Stock

Alta Equipment Group Inc

Alta Equipment Group Inc. Depositary Shares (each representing 1/1000th in a share of 10% Series A Cumulative Perpetual Preferred Stock)

ALTECH CHEMICALS LTD by Altech Chemicals Ltd.

Altech Batteries Ltd

AlTi Global Inc

Pacer Lunt Large Cap Alternator ETF

Arcadium Lithium PLC

Kinetik Holdings Inc Warrants (09/11/2023)

ALTERNUS ENERGY GROUP PLC by ALTERNUS ENERGY GROUP PLC.

Alternus Energy Group PLC

Alto Ingredients Inc

Altamont Pharma Acquisition Corp

ALTIPLANO METALS INC ORD by Altiplano Metals Inc.

Altiplano Metals Inc

Altair Engineering Inc. - Class A Common Stock

Altair Engineering Inc

Altitude Acquisition Corp. III

Altitude Acquisition Corp Ordinary Shares - Class A

Altitude Acquisition Corp

Altitude Acquisition Corp Units (1 Ord Share Class A & 1/2 War)

Altitude Acquisition Corp Warrants (30/11/2027)

ALTEX INDUS INC by Altex Industries, Inc.

Altex Industries Inc

Global X Alternative Income ETF

Altimmune's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NYSE">ALT</a>) short percent of float has risen 15.72% since its last report. The company recently reported that it has 12.51 million shares sold short, which is 17.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.51 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Altimmune Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1712581229_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Altimmune has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Altimmune's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Altimmune's peer group average for short interest as a percentage of float is 11.64%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Altimmune?

Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) has outperformed the market over the past 5 years by 11.42% on an annualized basis producing an average annual return of 23.99%. Currently, Altimmune has a market capitalization of $653.65 million. 
Buying $100 In ALT: If an investor had bought $100 of ALT stock 5 years ago, it would be worth $288.51 today based on a price of $9.22 for ALT at the time of writing.
<h3>Altimmune's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1712176273_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today

HC Wainwright &amp; Co. analyst Patrick Trucchio maintains Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Buy and lowers the price target from $15 to $12.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $12

Shares of Kodiak Sciences Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kod#NASDAQ">KOD</a>) fell sharply during Thursday&rsquo;s session after the company reported a wider-than-expected fourth-quarter loss.
Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share.
Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Avalo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avtx#NASDAQ">AVTX</a>) shares jumped 430% to $25.35 after the company announced it acquired a Phase 2-ready anti-IL-1&beta; mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million.</li>
<li>Xilio Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xlo#NASDAQ">XLO</a>) gained 146% to $1.58 after the company announced an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. The company announced a $11.3 million private placement equity financing.</li>
<li>Biodexa Pharmaceuticals Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bdrx#NASDAQ">BDRX</a>) shares climbed 80% to $1.5395. Biodexa&#39;s MTX110 showed promise in extending life expectancy against aggressive brain cancers.</li>
<li>Ontrak, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otrk#NASDAQ">OTRK</a>) gained 55% to $0.9239.</li>
<li>Binah Capital Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcg#NASDAQ">BCG</a>) gained 48% to $14.05 after dipping more than 20% on Wednesday.</li>
<li>Kidpik Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pik#NASDAQ">PIK</a>) gained 40.7% to $4.5999. Kidpik recently regained compliance with the Nasdaq minimum bid price requirement.</li>
<li>Allego N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allg#NASDAQ">ALLG</a>) rose 32.8% to $1.7650.</li>
<li>Akanda Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akan#NASDAQ">AKAN</a>) gained 28% to $0.2053 after the company announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry.</li>
<li>Destiny Tech100 Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) rose 26% to $22.15.</li>
<li>REX American Resources Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rex#NYSE">REX</a>) gained 23.2% to $54.15 following upbeat earnings.</li>
<li>Nutriband Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntrb#NASDAQ">NTRB</a>) gained 23% to $4.98. Nutriband recently provided a clinical and regulatory path overview for its AVERSA Fentanyl patch.</li>
<li>Summit Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smmt#NASDAQ">SMMT</a>) gained 22.8% to $4.6050.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cero#NASDAQ">CERO</a>) gained 22.7% to $2.00.</li>
<li>Hut 8 Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hut#NASDAQ">HUT</a>) gained 20.4% to $11.87. Hut 8 Corp reported revenue of C$60.6 million for the six months ended Dec. 31, 2023.</li>
<li>Matterport, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mttr#NASDAQ">MTTR</a>) rose 16.8% to $2.2802.</li>
<li>RH (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rh#NYSE">RH</a>) rose 16.2% to $344.99 following the release of quarterly results. RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast.</li>
<li>Cazoo Group Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/czoo#NASDAQ">CZOO</a>) gained 15.5% to $14.52 after jumping over 100% on Wednesday.</li>
<li>Sutro Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stro#NASDAQ">STRO</a>) surged 14.4% to $5.64. Oppenheimer analyst Jay Olson maintained Sutro Biopharma with an Outperform and maintained a $10 price target.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) shares rose 14.1% to $0.1021. Kintara Therapeutics announced expansion of REM-001 clinical study to include patients on pembrolizumab.</li>
<li>Nikola Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nkla#NASDAQ">NKLA</a>) gained 12.7% to $1.0250.</li>
<li>OPKO Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opk#NASDAQ">OPK</a>) climbed 12.1% to $1.1996. Labcorp announced acquisition of select assets of BioReference Health&#39;s Diagnostics Business.</li>
<li>Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>) climbed 11.4% to $9.90. Altimmune recently released lean mass preservation data for pemvidutide and worse-than-expected fourth-quarter FY23 earnings.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mara#NASDAQ">MARA</a>) gained 10.4% to $24.37.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dna#NYSE">DNA</a>) rose 7.1% to $1.1786. Ginkgo Bioworks announced that it has been awarded a contract for up to $6 million from the Defense Advanced Research Projects Agency.</li>
<li>The Est&eacute;e Lauder Companies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/el#NYSE">EL</a>) gained 5.4% to $152.85 after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $160 to $170.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Primech Holdings Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmec#NASDAQ">PMEC</a>) shares fell 46.7% to $2.07 after the company issued financial updates and corporate highlights for the six months ended Sept. 30, 2023.</li>
<li>Gamida Cell Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gmda#NASDAQ">GMDA</a>) fell 28.1% to $0.0427. Gamida Cell shares dipped over 82% on Wednesday after the company reported fourth-quarter results and disclosed the commencement of a restructuring process.</li>
<li>Data Storage Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtst#NASDAQ">DTST</a>) dipped 24% to $5.81 following fourth-quarter results.</li>
<li>urban-gro, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ugro#NASDAQ">UGRO</a>) declined 22.9% to $1.3992 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Presto Automation Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prst#NASDAQ">PRST</a>) fell 22% to $0.1493. Presto Automation recently entered securities purchase agreements relating to the issuance and sale of 4.8 million shares</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tnxp#NASDAQ">TNXP</a>) dipped 19.6% to $0.2629. Tonix Pharmaceuticals announced pricing of $4.4 million registered direct offering.</li>
<li>MillerKnoll, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlkn#NASDAQ">MLKN</a>) shares fell 17.2% to $25.28 as the company reported downbeat sales for its third quarter and issued weak guidance for the fourth quarter.</li>
<li>Sezzle Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sezl#NASDAQ">SEZL</a>) fell 16.6% to $77.13.</li>
<li>NuCana plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncna#NASDAQ">NCNA</a>) fell 16.3% to $0.2616. NuCana announced a plan to implement 1-for-25 ADS ratio change.</li>
<li>SOBR Safe, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sobr#NASDAQ">SOBR</a>) fell 13.7% to $0.4460 after gaining 12% on Wednesday.</li>
<li>Murano Global Investments Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrno#NASDAQ">MRNO</a>) fell 13% to $12.97.</li>
<li>22nd Century Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xxii#NASDAQ">XXII</a>) fell 12.5% to $ 0.1151 as the company posted fourth-quarter results and announced stock split of 1-for-16.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) declined 10.9% to $1,710.01.</li>
<li>Hitek Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hkit#NASDAQ">HKIT</a>) fell 10.3% to $1.56 after gaining over 22% on Wednesday.</li>
<li>Movella Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mvla#NASDAQ">MVLA</a>) fell 10.2% to $0.0678 after dipping 20% on Wednesday.</li>
<li>Abits Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abts#NASDAQ">ABTS</a>) fell 10.2% to $0.70.</li>
<li>Reddit, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rddt#NYSE">RDDT</a>) fell 9.4% to $52.32.</li>
<li>Braze, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brze#NASDAQ">BRZE</a>) dipped 9.3% to $45.90 after the company issued soft EPS guidance for FY25.</li>
<li>The Chemours Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cc#NYSE">CC</a>) shares dropped 6.2% to $27.09 after the company reported fourth-quarter results. The company also said it identified four material weaknesses amid its internal control over financial reporting.</li>
<li>GCT Semiconductor Holding Inc, (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gcts#NYSE">GCTS</a>) fell 5.1% to $41.77 amid volatility following the company&#39;s recently completed business combination with Concord Acquisition Corp III and NYSE debut.</li>
<li>Carnival Corporation &amp; plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ccl#NYSE">CCL</a>) fell 4% to $16.52. Carnival posted a narrower-than-expected loss for its first quarter on Wednesday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37975916/jim-cramer-likes-crown-castle-but-cant-recommend-archer-aviation-it-has-no-earnings-powe"> Jim Cramer Likes Crown Castle, But Can&#39;t Recommend Archer Aviation: It Has &#39;No Earnings Power&#39; </a>

Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

B. Riley Securities analyst Mayank Mamtani reiterates Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Buy and maintains $20 price target.

Reiteration

B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target

U.S. stocks were slightly higher, with the S&amp;P 500 gaining around 0.1% on Thursday.
Shares of REX American Resources Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rex#NYSE">REX</a>) rose sharply during Thursday&rsquo;s session following <a href="https://www.benzinga.com/quote/REX/earnings">upbeat quarterly earnings.</a>
REX American Resources posted quarterly GAAP earnings of $1.16 per share, versus market estimates of 68 cents per share, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
REX American Resources shares jumped 23.2% to $54.15 on Thursday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Avalo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avtx#NASDAQ">AVTX</a>) shares gained 430% to $25.35 after the company announced it acquired a Phase 2-ready anti-IL-1&beta; mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million.</li>
<li>Hut 8 Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hut#NASDAQ">HUT</a>) surged 20.4% to $11.87. Hut 8 Corp reported revenue of C$60.6 million for the six months ended Dec. 31, 2023.</li>
<li>RH (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rh#NYSE">RH</a>) gained 16.2% to $344.99 following the release of quarterly results. RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast.</li>
<li>Sutro Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stro#NASDAQ">STRO</a>) climbed 14.4% to $5.64. Oppenheimer analyst Jay Olson maintained Sutro Biopharma with an Outperform and maintained a $10 price target.</li>
<li>Nikola Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nkla#NASDAQ">NKLA</a>) rose 12.7% to $1.0250.</li>
<li>OPKO Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opk#NASDAQ">OPK</a>) rose 12.1% to $1.1996. Labcorp announced acquisition of select assets of BioReference Health&#39;s Diagnostics Business.</li>
<li>Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>) gained 11.4% to $9.90. Altimmune recently released lean mass preservation data for pemvidutide and worse-than-expected fourth-quarter FY23 earnings.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mara#NASDAQ">MARA</a>) climbed 10.4% to $24.37.</li>
<li>Guardant Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gh#NASDAQ">GH</a>) gained 8.4% to $19.48.</li>
<li>Opendoor Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/open#NASDAQ">OPEN</a>) surged 8% to $3.1850.</li>
<li>Arhaus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arhs#NASDAQ">ARHS</a>) gained 7.7% to $15.94.</li>
<li>Riot Platforms, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/riot#NASDAQ">RIOT</a>) rose 6.8% to $13.07.</li>
<li>BRP Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dooo#NASDAQ">DOOO</a>) gained 6.4% to $67.74 after the company reported fourth-quarter results.</li>
<li>Encompass Health Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ehc#NYSE">EHC</a>) gained 5.8% to $82.06. Barclays analyst Andrew Mok maintained Encompass Health with an Overweight and raised the price target from $95 to $101.</li>
<li>The Est&eacute;e Lauder Companies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/el#NYSE">EL</a>) rose 5.4% to $152.85 after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $160 to $170.</li>
<li>Exact Sciences Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exas#NASDAQ">EXAS</a>) gained 4.7% to $70.01.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37984469/bitcoin-trades-above-70-000-following-gdp-jobless-claims-data-gatetoken-emerges-as-top-gai"> Bitcoin Trades Above $70,000 Following GDP, Jobless Claims Data; GateToken Emerges As Top Gainer</a>

Wednesday,&nbsp;Altimmune Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) said the body composition study of pemvidutide showed lean mass preservation, with 25.5% of weight loss derived from lean mass with 74.5% of weight loss from adipose tissue, comparable to the effects historically associated&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/g37953807/altimmune-announces-positive-lean-mass-preservation-data-for-pemvidutide-and-reports-fourth-quarte" rel="noreferrer noopener">with diet and exercise</a>.
Altimmune will present the complete data analysis at an upcoming scientific meeting.
In December 2023, Altimmune announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36042805/tale-of-two-investigational-obesity-drugs-altimmune-stock-jumps-while-pfizer-trades-lower" rel="noreferrer noopener">with 391 subjects</a>.&nbsp;
At Week 48, subjects receiving pemvidutide achieved mean weight losses of 10.3%, 11.2%, 15.6%, and 2.2% at the 1.2 mg, 1.8 mg, and 2.4 mg doses and placebo, respectively, with the near-linear trajectory of continued weight loss observed on the 2.4 mg dose at the end of treatment.&nbsp;
Pemvidutide is also being developed for Metabolic dysfunction-associated steatohepatitis (MASH). Enrollment is ongoing in the IMPACT biopsy-driven Phase 2b MASH trial.
Topline results after 24 weeks of treatment are expected in the first quarter of 2025.
In February, Kerrisdale Capital&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/02/37313729/altimmune-stock-surges-kerrisdale-remains-short-what-you-need-to-know" rel="noreferrer noopener">announced a short position</a>&nbsp;in the stock, claiming the company had little chance of competing against others in the GLP-1 space and calling it an "obvious dead end."
"Even if pemvidutide did result in 15.6% weight loss, that's not good enough," Kerrisdale said at the time.
Recently,&nbsp;&nbsp;Biohaven's&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NASDAQ">BHVN</a>) CEO Vlad Coric said, "What we are trying to do is result in significant weight loss without losing muscle mass, which is what we see with the GLPs."
In October 2023, Biohaven presented preclinical data demonstrating the ability of taldefgrobep alfa to significantly reduce fat mass while increasing lean mass in an&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37942782/obesity-drug-landscape-has-a-contender-from-biohaven-ceo-highlights-different-approach-amid-stiff" rel="noreferrer noopener">obese mouse model</a>.&nbsp;
Altimmune reported a fourth-quarter 2023 EPS loss of $(0.54), missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $(0.43)</a>.
Altimmune had cash, cash equivalents, and short-term investments totaling $198.0 million&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/g37953807/altimmune-announces-positive-lean-mass-preservation-data-for-pemvidutide-and-reports-fourth-quarte" rel="noreferrer noopener">at December 31, 2023</a>.
Price Action:&nbsp;ALT shares are higher by 7.51% at $9.31 during the premarket session on the last check Wednesday.

<h3>Gainers</h3>
<ul>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares moved upwards by 67.2% to $3.77 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.4 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares rose 24.34% to $3.78. The company's market cap stands at $31.9 million. </li>
<li>NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) stock rose 17.9% to $15.41. The company's market cap stands at $1.6 billion. </li>
<li>Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) shares increased by 14.93% to $0.53. The market value of their outstanding shares is at $18.5 million. As per the news, the Q4 earnings report came out today. </li>
<li>Nuvation Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) shares moved upwards by 11.11% to $3.2. The market value of their outstanding shares is at $700.9 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares rose 10.29% to $1.5. The company's market cap stands at $73.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) stock decreased by 20.6% to $0.3 during Wednesday's pre-market session. The company's market cap stands at $23.7 million. </li>
<li>OpGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>) stock fell 15.67% to $0.63. The market value of their outstanding shares is at $6.3 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares declined by 14.76% to $3.35. The company's market cap stands at $339.9 million. </li>
<li>Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) stock declined by 12.72% to $7.55. The market value of their outstanding shares is at $405.6 million. As per the press release, Q4 earnings came out today. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) stock decreased by 12.68% to $0.53. The company's market cap stands at $23.0 million. </li>
<li>PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) shares decreased by 12.28% to $3.93. The company's market cap stands at $122.2 million. The company's, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKLI

LIXT

MESO

MNOV

NUVB

NVCR

OPGN

PDSB

SSKN

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

Altimmune shares are trading lower after the company released lean mass preservation data for pemvidutide and worse-than-expected Q4 FY23 earnings.

Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.43) by 25.58 percent. This is a 25.58 percent decrease over losses of $(0.43) per share from the same period last year. The company reported $37.00 thousand in sales this quarter. This is a 133.64 percent increase over sales of $(110.00 thousand) the same period last year.

Altimmune Q4 GAAP EPS $(0.54) Misses $(0.43) Estimate, Sales $37.00K Up From $(110.00K) YoY

Altimmune Announces Lean Mass Preservation Data For Pemvidutide From Body Composition Study Showing 25.5% Of Weight Loss Derived From Lean Mass And 74.5% Of Weight Loss Was Derived From Adipose Tissue

<h3>Companies Reporting Before The Bell</h3>
&bull; Local Bounti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOCL#NYSE">LOCL</a>) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
&bull; REE Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) is estimated to report quarterly loss at $2.38 per share on revenue of $1.35 million.
&bull; Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) is projected to report quarterly loss at $2.05 per share on revenue of $12.48 million.
&bull; Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) is expected to report quarterly loss at $0.05 per share on revenue of $19.66 million.
&bull; Vanguard Extended Duration Treasury ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDV#NYSE">EDV</a>) is expected to report earnings for its fourth quarter.
&bull; Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) is likely to report earnings for its fourth quarter.
&bull; Gamida Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMDA#NASDAQ">GMDA</a>) is projected to report quarterly loss at $0.15 per share on revenue of $1.06 million.
&bull; PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) is likely to report earnings for its fourth quarter.
&bull; Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) is projected to report earnings for its fourth quarter.
&bull; Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) is estimated to report quarterly loss at $1.14 per share on revenue of $2.00 million.
&bull; Lands&#39; End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $502.71 million.
&bull; Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) is projected to report quarterly earnings at $3.58 per share on revenue of $2.39 billion.
&bull; GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) is projected to report earnings for its fourth quarter.
&bull; Sonida Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDA#NYSE">SNDA</a>) is projected to report earnings for its fourth quarter.
&bull; UniFirst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) is projected to report quarterly earnings at $1.42 per share on revenue of $587.84 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Creative Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>) is estimated to report quarterly loss at $0.48 per share on revenue of $30.20 million.
&bull; Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) is likely to report earnings for its fourth quarter.
&bull; VNET Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) is projected to report quarterly loss at $0.18 per share on revenue of $279.03 million.
&bull; RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) is estimated to report quarterly earnings at $1.67 per share on revenue of $777.48 million.
&bull; American Shared Hospital (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMS#AMEX">AMS</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $5.19 million.
&bull; Cosan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSAN#NYSE">CSAN</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $7.45 billion.
&bull; Greenidge Generation Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $26.70 million.
&bull; Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $21.00 million.
&bull; Allied Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGAE#NASDAQ">AGAE</a>) is projected to report earnings for its fourth quarter.
&bull; Jefferies Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $1.52 billion.
&bull; LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) is expected to report quarterly loss at $1.73 per share on revenue of $2.28 million.
&bull; H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) is projected to report quarterly earnings at $0.64 per share on revenue of $825.03 million.
&bull; Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $188.73 million.
&bull; Dynagas LNG Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLNG#NYSE">DLNG</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $38.21 million.
&bull; Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) is estimated to report quarterly loss at $0.33 per share on revenue of $2.48 million.
&bull; Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) is expected to report earnings for its fourth quarter.
&bull; BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $90 thousand.
&bull; Consolidated Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) is likely to report quarterly earnings at $0.44 per share on revenue of $45.25 million.
&bull; Silver Spike Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSIC#NASDAQ">SSIC</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $3.37 million.
&bull; Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $28.94 million.
&bull; PLBY Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $32.27 million.
&bull; Usio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USIO#NASDAQ">USIO</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $20.43 million.
&bull; Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $62.02 million.
&bull; Super League Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) is estimated to report quarterly loss at $1.20 per share on revenue of $9.30 million.
&bull; Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $4.60 million.
&bull; Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $10.01 million.
&bull; Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) is estimated to report quarterly earnings at $0.97 per share on revenue of $263.12 million.
&bull; Eastside Distilling (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) is projected to report quarterly loss at $0.90 per share on revenue of $3.68 million.
&bull; Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is likely to report quarterly loss at $0.05 per share on revenue of $124.86 million.
&bull; Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) is expected to report quarterly loss at $0.11 per share on revenue of $82.04 million.
&bull; Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) is expected to report quarterly loss at $0.05 per share on revenue of $50 thousand.
&bull; Kingstone Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KINS#NASDAQ">KINS</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $29.65 million.
&bull; MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $909.50 million.
&bull; Rumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) is likely to report quarterly loss at $0.22 per share on revenue of $28.13 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AGAE

AQMS

BCDA

CELC

CLRB

CMCT

CSAN

CTAS

CWCO

DLNG

DPRO

DRRX

DTIL

EAST

EDAP

GAIA

GLYC

GREE

KINS

LGMK

LOCL

MDAI

PLBY

SNDA

SSIC

SYRS

USIO

VNET

VRNT

Earnings Scheduled For March 27, 2024

Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-03-27. Here's what investors need to know before the announcement.
Analysts estimate that Altimmune will report an earnings per share (EPS) of $-0.43. 
Altimmune bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.03, which was followed by a 0.0% drop in the share price the next day.
Here's a look at Altimmune's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.42</td>
<td>-0.46</td>
<td>-0.48</td>
<td>-0.50</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.39</td>
<td>-0.32</td>
<td>-0.40</td>
<td>-0.43</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-1.0%</td>
<td>-5.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711465256_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Altimmune were trading at $8.53 as of March 25. Over the last 52-week period, shares are up 99.31%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ALT/earnings">To track all earnings releases for Altimmune visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Altimmune's Earnings Outlook

Altimmune's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NYSE">ALT</a>) short percent of float has risen 15.44% since its last report. The company recently reported that it has 11.55 million shares sold short, which is 21.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.33 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Altimmune Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1711114219_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Altimmune has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Altimmune's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Altimmune's peer group average for short interest as a percentage of float is 6.76%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(ALT) - Analyzing Altimmune's Short Interest

On CNBC&rsquo;s &quot;Mad Money Lightning Round,&quot; Jim Cramer said Marvell Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrvl#NASDAQ">MRVL</a>) reported a mixed quarter. &quot;<a href="https://www.benzinga.com/news/24/03/37756021/marvells-latest-tech-leap-with-tsmc-a-2nm-chip-platform-set-to-transform-ai-infrastructure">We got to wait,&quot; he added. </a>
Last week, Marvell Technology unveiled a significant development in semiconductor technology through an expanded partnership with Taiwan Semiconductor Manufacturing Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tsm#NYSE">TSM</a>), launching the first-ever 2nm silicon intellectual property (IP) technology platform.
Cramer recommended buying Datadog, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ddog#NASDAQ">DDOG</a>), saying that it is a &quot;dynamite&quot; company. &quot;It is expensive, but they really know what they&rsquo;re doing,&quot; he noted.
On Feb. 13, Datadog posted upbeat sales for its fourth quarter, but issued FY24 EPS guidance below estimates. The company clocked fourth-quarter FY23 revenue growth of 26% year-on-year to $589.649 million, beating the consensus of $568.695 million.
When asked about Centrus Energy Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/leu#NYSE">LEU</a>), he said, &quot;Very speculative situation. I want you to buy the GE spinoff that&rsquo;s coming, it&rsquo;s Vernova. That has got nuke, and I love the balance sheet, and I love what the company&rsquo;s doing, and you want to be a little diversified.&quot;
On Feb. 8, Centrus Energy reported better-than-expected fourth-quarter financial results.
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>) is an &quot;absolute, without a doubt, high-risk stock, when you could have Eli Lilly (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>),&quot; Cramer said.
Last month, Kerrisdale Capital announced a short position in the stock, claiming the company had little chance of competing against others in the GLP-1 space and calling it an &ldquo;<a href="https://www.benzinga.com/24/02/37102984/altimmune-stock-sinks-as-kerrisdale-capital-announces-short-position-obvious-dead-end">obvious dead end</a>.&rdquo;
When asked about Lantheus Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lnth#NASDAQ">LNTH</a>), he said, &quot;I&rsquo;ve been preferring RadNet (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>), because I think they&rsquo;ve got a better business model.&quot;
On March 4, Lantheus announced the FDA approval of DEFINITY for pediatric patients.
&quot;They were doing great, and then they did this convertible bond, and it just wrecked the stock,&quot; the &quot;Mad Money&quot; host said about SoFi Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sofi#NASDAQ">SOFI</a>). &quot;The stock has just been in the dog house ever since, and I don&rsquo;t like it when I tell people to buy a stock and it&rsquo;s staying in the dog house. We got to find out what the heck is going on there.&quot;
On March 5, SoFi Technologies announced a proposed $750 million convertible senior notes offering due 2029.
Cramer said On Holding AG (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/onon#NYSE">ONON</a>) had a &quot;controversial&quot; quarter. &quot;I am on the fence on On,&quot; he added.
<h3>Price Action</h3>
<ul>
<li>Shares of Marvell Technology gained 0.5% to close at $67.20 on Monday.</li>
<li>Datadog shares gained 0.4% to close at $120.87 on Monday.</li>
<li>Centrus Energy shares gained 1.4% to settle at $38.77.</li>
<li>Altimmune shares dipped 7.9% to settle at $9.08 on Monday.</li>
<li>Lantheus shares fell 2.8% to close at $56.52 on Monday.</li>
<li>Shares of SoFi rose 0.7% to settle at $7.08.</li>
<li>On Holding shares fell 0.4% to close at $33.10 on Monday.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37780512/traeger-and-3-other-stocks-under-5-insiders-are-buying"> Traeger And 3 Other Stocks Under $5 Insiders Are Buying</a>
Image: Shutterstock

Long Ideas

Media

DDOG

LNTH

MRVL

ONON

RDNT

SOFI

Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'

Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) has outperformed the market over the past 5 years by 13.87% on an annualized basis producing an average annual return of 26.86%. Currently, Altimmune has a market capitalization of $522.24 million. 
Buying $100 In ALT: If an investor had bought $100 of ALT stock 5 years ago, it would be worth $311.00 today based on a price of $9.72 for ALT at the time of writing.
<h3>Altimmune's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1710781222_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Today

Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) has outperformed the market over the past 5 years by 24.97% on an annualized basis producing an average annual return of 37.62%. Currently, Altimmune has a market capitalization of $706.53 million. 
Buying $100 In ALT: If an investor had bought $100 of ALT stock 5 years ago, it would be worth $499.25 today based on a price of $13.15 for ALT at the time of writing.
<h3>Altimmune's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1709155824_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Shares of Helix Energy Solutions Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlx#NYSE">HLX</a>) fell sharply during Tuesday&rsquo;s session following weak earnings.
Helix Energy posted adjusted earnings of 6 cents per share, missing market estimates of 10 cents per share. The company&rsquo;s quarterly sales came in at $335.16 million versus expectations of $315.60 million.
Helix Energy Solutions shares dipped 11% to $9.13 on Tuesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/janx#NASDAQ">JANX</a>) shares jumped 145% to $37.00 after the company announced updated clinical data for both of its clinical programs.</li>
<li>Presto Automation Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prst#NASDAQ">PRST</a>) surged 72% to $0.5657.</li>
<li>Viking Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vktx#NASDAQ">VKTX</a>) shares jumped 71.2% to $65.88 after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints.</li>
<li>CXApp Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cxai#NASDAQ">CXAI</a>) gained 67% to $2.58.</li>
<li>WeTrade Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wetg#NASDAQ">WETG</a>) gained 50% to $3.36.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>) climbed 33.6% to $13.70 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>Biora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bior#NASDAQ">BIOR</a>) surged 32.2% to $1.39.</li>
<li>AdaptHealth Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ahco#NASDAQ">AHCO</a>) jumped 29.6% to $9.89 following fourth-quarter results.</li>
<li>Codexis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdxs#NASDAQ">CDXS</a>) rose 29% to $4.1283. Codexis entered into exclusive licensing agreement with Roche for double-stranded DNA Ligase.</li>
<li>Beam Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/beam#NASDAQ">BEAM</a>) gained 26.8% to $45.43 after the company reported fourth-quarter financial results.</li>
<li>BigBear.ai Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbai#NYSE">BBAI</a>) rose 26% to $3.14. Cantor Fitzgerald analyst Yi Fu Lee maintained BigBear.ai with an Overweight and maintained $3 price target.</li>
<li>5E Advanced Materials, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/feam#NASDAQ">FEAM</a>) gained 24.3% to $1.84.</li>
<li>Earlyworks Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elws#NASDAQ">ELWS</a>) gained 24.2% to $0.7321. Earlyworks was selected as a co-creation partner for MetaMe&reg; a meta-communication service utilizing cutting-edge technology from NTT DOCOMO, one of Japan&#39;s largest cell phone operators.</li>
<li>The Singing Machine Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mics#NASDAQ">MICS</a>) rose 24.1% to $0.9012.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smx#NASDAQ">SMX</a>) jumped 24% to $0.3299.</li>
<li>Ligand Pharmaceuticals Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgnd#NASDAQ">LGND</a>) gained 23% to $91.68 following upbeat quarterly earnings.</li>
<li>SoundHound AI, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/soun#NASDAQ">SOUN</a>) jumped 22.3% to $7.03 after gaining more than 46% on Monday.</li>
<li>Pyxis Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pyxs#NASDAQ">PYXS</a>) gained 21.3% to $5.80. Pyxis Oncology announced a $50 million private placement.</li>
<li>PubMatic, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pubm#NASDAQ">PUBM</a>) shares climbed 20.8% to $20.01 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>bluebird bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blue#NASDAQ">BLUE</a>) jumped 20.5% to $1.76.</li>
<li>Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>) gained 20.4% to $13.63.</li>
<li>Sterling Infrastructure, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/strl#NASDAQ">STRL</a>) jumped 19% to $107.00 after the company reported fourth-quarter financial results.</li>
<li>Denali Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dnli#NASDAQ">DNLI</a>) gained 17.6% to $19.87 following quarterly results.</li>
<li>National Vision Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eye#NASDAQ">EYE</a>) rose 17.6% to $23.48 following strong results.</li>
<li>Heidrick &amp; Struggles International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsii#NASDAQ">HSII</a>) gained 16.7% to $33.81 following strong results.</li>
<li>Ault Alliance, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ault#NASDAQ">AULT</a>) rose 15.8% to $0.4520. Ault Alliance announced record preliminary 2023 revenue of $153 million.</li>
<li>Portillo&#39;s Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ptlo#NASDAQ">PTLO</a>) gained 15.6% to $15.90 following upbeat results.</li>
<li>Dorman Products, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dorm#NASDAQ">DORM</a>) climbed 11.5% to $92.67 following upbeat earnings.</li>
<li>Constellation Energy Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ceg#NASDAQ">CEG</a>) gained 9.7% to $146.27 following strong sales..</li>
<li>NovoCure Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvcr#NASDAQ">NVCR</a>) gained 9.5% to $16.31.</li>
<li>TransMedics Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) gained 9.5% to $85.14 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Minerva Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nerv#NASDAQ">NERV</a>) shares dipped 56.9% to $2.93 after the company announced it received a Complete Response Letter from the FDA for the New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) fell 55.8% to $1.2180. The stock continues to experience marked volatility after the company on Monday said it encountered an unexpected delay in its planned reverse stock split.</li>
<li>NRx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrxp#NASDAQ">NRXP</a>) fell 32.7% to $0.2878 after the company announced pricing of $1.5 million underwritten public offering of common stock at a price of $0.30/share together with investor commitment for additional $1 million.</li>
<li>Thoughtworks Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/twks#NASDAQ">TWKS</a>) fell 30.6% to $3.20 after the company reported worse-than-expected fourth-quarter financial results and issued weak guidance.</li>
<li>Alpine 4 Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alpp#NASDAQ">ALPP</a>) dipped 26% to $0.8799.</li>
<li>Stagwell Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stgw#NASDAQ">STGW</a>) fell 25.6% to $5.22 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Calidi Biotherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cldi#NASDAQ">CLDI</a>) dipped 24.9% to $0.9084.</li>
<li>Clarivate Plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/clvt#NYSE">CLVT</a>) fell 23.3% to $6.85 after the company reported fourth-quarter financial results and issued guidance.</li>
<li>Edgio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egio#NASDAQ">EGIO</a>) fell 21.5% to $0.2450. Edgio announced effectiveness of reverse stock split.</li>
<li>Telesis Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tbio#NASDAQ">TBIO</a>) fell 21% to $0.5215 after tumbling 15% on Monday. Telesis Bio said it sees preliminary 2023 total consolidated revenue of $27.5 million.</li>
<li>Lotus Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lot#NASDAQ">LOT</a>) dipped 20.3% to $11.36.</li>
<li>Pineapple Energy Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pegy#NASDAQ">PEGY</a>) shares fell 19.6% to $0.0654. On Feb. 5. Pineapple Energy priced a $1 million registered direct offering of common stock.</li>
<li>The Aaron&#39;s Company, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aan#NYSE">AAN</a>) shares fell 16.7% to $8.71. Aaron&#39;s reported a loss for the fourth quarter, while sales missed estimates.</li>
<li>Perrigo Company plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/prgo#NYSE">PRGO</a>) fell 15.1% to $27.33 after the company reported fourth quarter financial results.</li>
<li>Intuitive Machines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lunr#NASDAQ">LUNR</a>) fell 10% to $5.64. Intuitive Machines said communications with moon lander Odysseus is expected to cease Tuesday morning, effectively ending mission 5 days after touchdown, Reuters reported.</li>
<li>Unity Software Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/u#NYSE">U</a>) fell 8.3% to $30.31 after the company reported mixed financial results for its fourth quarter. The company said it sees first-quarter strategic portfolio revenue in the range of $415 million to $420 million.</li>
<li>Primoris Services Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prim#NASDAQ">PRIM</a>) dipped 7.2% to $ 37.63 after the company reported mixed fourth quarter financial results.</li>
<li>LendingTree, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tree#NASDAQ">TREE</a>) fell 6.9% to $31.90 following weak sales.</li>
<li>CarGurus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/carg#NASDAQ">CARG</a>) shares fell 4.2% to $22.89 after the company reported fourth-quarter financial results.</li>
<li>Workday, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wday#NASDAQ">WDAY</a>) shares declined 2.9% to $298.42 after the company reported fourth-quarter financial results, reiterated guidance and announced its intent to acquire HiredScore.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/37328014/how-to-earn-500-a-month-from-ebay-stock-ahead-of-q4-earnings-report"> How To Earn $500 A Month From eBay Stock Ahead Of Q4 Earnings Report </a>

AHCO

ALPP

AULT

BBAI

BEAM

BIOR

BLUE

CARG

CDXS

CLDI

CLVT

CXAI

DNLI

DORM

EGIO

ELWS

FEAM

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSII

IFBD

JANX

LGND

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session